Return to content in this issue

 

Successful Desensitization to Alemtuzumab, With Flow Cytometry Analysis of Peripheral Blood Cells

Costa Carvalho J1, Macário MC2, Batista S2, Alen Coutinho I1, Laranjeira P3,4,5,6, Loureiro C1, Paiva A3,4,5,7, Todo Bom A1,8

1Allergy and Clinical Immunology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal
2Neurology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal
3Flow Cytometry Unit, Clinical Pathology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal
4Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
5Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
6Center for Neuroscience and Cell Biology (CNC), University of
Coimbra, Coimbra, Portugal
7Instituto Politécnico de Coimbra, ESTESC-Coimbra Health School, Ciências Biomédicas Laboratoriais, Coimbra, Portugal
8Institute of Pathophysiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

J Investig Allergol Clin Immunol 2022; Vol 32(6) : 501-503
doi: 10.18176/jiaci.0795

Key words: Alemtuzumab, Desensitization, Flow cytometry, Hypersensitivity, Multiple sclerosis